Liver growth factor treatment reverses vascular and plasmatic oxidative stress in spontaneously hypertensive rats

Journal of Hypertension

Volumn 30, Issue 6, 2012, Pages 1185-1194

  Condezo Hoyos, Luis ^a   Arribas, Silvia M ^a   Abderrahim, Fátima ^a   Somoza, Beatriz ^b   Gil Ortega, Marta ^b   Díaz Gil, Juan J ^c   Conde, M Victoria ^a   Susin, Cristina ^a   González, M Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

NADPH oxidase; oxidative stress; SHR; superoxide anion; xanthine oxidase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; CATALASE; GROWTH FACTOR; HYDROETHIDINE; LIVER GROWTH FACTOR; MALONALDEHYDE; MANGANESE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECTROPHOTOMETRY; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WISTAR KYOTO RAT;

EID: 84861101751     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328353824b     Document Type: Article

References (84)

1. Prabha PS, Das UN, Koratkar R, Sagar PS, Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Essent Fatty Acids 1990; 41:27-33.
2. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71:247-258.
3. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106:2800-2805.
4. Somers MJ,Mavromatis K,Galis ZS,HarrisonDG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000; 101:1722-1728.
5. Banday AA, Muhammad AB, Fazili FR, Lokhandwala M. Mechanisms of oxidative stress-induced increase in salt sensitivity and development of hypertension in Sprague-Dawley rats. Hypertension 2007; 49:664-671.
6. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38:1107-1111.
7. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 2000; 18:1795-1800.
8. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal 2008; 10:1045-1059.
9. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009; 93:621-635.
10. Delles C, Miller WH, Dominiczak AF. Targeting reactive oxygen species in hypertension. Antioxid Redox Signal 2008; 10:1061-1077.
11. Matsumoto S, Shimodozono M, Miyata R, Kawahira K. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. Hypertens Res 2009; 32:1015-1021.
12. Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009; 32:962-968.
13. Ciulla MM, Paliotti R, Esposito A, Cuspidi C, Muiesan ML, Rosei EA, et al. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensinconverting enzyme inhibitor, enalapril. J Hypertens 2009; 27:626-632.
14. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008; CD003823.
15. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1:43-50.
16. Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Smallmolecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 2009; 11:2535-2552.
17. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221-226.
18. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr., Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1107-1113.
19. Schneider MP, Delles C, Schmidt BM, Oehmer S, Schwarz TK, Schmieder RE, et al. Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am J Hypertens 2005; 18:1111-1117.
20. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membranepermeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998; 32:59-64.
21. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31 (Suppl 2):S170-S180.
22. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008; 31 (Suppl 2):S181-S184.
23. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003; 107:926-928.
24. Diaz-Gil JJ, Gavilanes JG, Sanchez G, Garcia-Canero R, Garcia-Segura JM, Santamaria L, et al. Identification of a liver growth factor as an albumin-bilirubin complex. Biochem J 1987; 243:443-448.
25. Diaz-Gil JJ, Sanchez G, Trilla C, Escartin P. Identification of biliprotein as a liver growth factor. Hepatology 1988; 8:484-486.
26. Diaz-Gil JJ, Escartin P, Garcia-Canero R, Trilla C, Veloso JJ, Sanchez G, et al. Purification of a liver DNA-synthesis promoter from plasma of partially hepatectomized rats. Biochem J 1986; 235:49-55.
27. Diaz-Gil JJ, Gavilanes JG, Garcia-Canero R, Garcia-Segura JM, Santamaria L, Trilla C, et al. Liver growth factor purified from human plasma is an albumin-bilirubin complex. Mol Biol Med 1989; 6:197-207.
28. Somoza B, Abderrahim F, Gonzalez JM, Conde MV, Arribas SM, Starcher B, et al. Short-term treatment of spontaneously hypertensive rats with liver growth factor reduces carotid artery fibrosis, improves vascular function, and lowers blood pressure. Cardiovasc Res 2006; 69:764-771.
29. Conde MV, Gonzalez MC, Quintana-Villamandos B, Abderrahim F, Briones AM, Condezo-Hoyos LA, et al. Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR. Am J Physiol Heart Circ Physiol 2011; 301:H1153-H1165.
30. Meziani F, Kremer H, Tesse A, Baron-Menguy C, Mathien C, Mostefai HA, et al. Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am J Pathol 2007; 171:1753-1761.
31. Wu ML, Ho YC, Yet SF. A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal 2011; 15:1835-1846.
32. Condezo-Hoyos L, Abderrahim F, Conde MV, Susin C, Diaz-Gil JJ, Gonzalez MC, et al. Antioxidant activity of liver growth factor, a bilirubin covalently bound to albumin. Free Radic Biol Med 2009; 46:656-662.
33. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186:407-421.
34. Hawkins CL, Morgan PE, Davies MJ. Quantification of protein modification by oxidants. Free Radical Biol Med 2009; 46:965-988.
35. Dolhofer R, Wieland OH. Improvement of the thiobarbituric acid assay for serum glycosylprotein determination. Clin Chim Acta 1981; 112:197-204.
36. Laurentin A, Edwards CA. A microtiter modification of the anthronesulfuric acid colorimetric assay for glucose-based carbohydrates. Analytical Biochem 2003; 315:143-145.
37. Arribas SM, Hermida C, Gonzalez MC, Wang Y, Hinek A. Enhanced survival of vascular smooth muscle cells accounts for heightened elastin deposition in arteries of neonatal spontaneously hypertensive rats. Exp Physiol 2010; 95:550-560.
38. Gonzalez JM, Somoza B, Conde MV, Fernandez-Alfonso MS, Gonzalez MC, Arribas SM. Hypertension increases middle cerebral artery resting tone in spontaneously hypertensive rats: role of tonic vasoactive factor availability. Clin Sci (Lond) 2008; 114:651-659.
39. Skatchkov MP, Sperling D, Hink U, Ä nggard E, Münzel T. Quantification of superoxide radical formation in intact vascular tissue using aCypridinaLuciferin analog as an alternative to lucigenin. Biochem Biophys Res Commun 1998; 248:382-386.
40. Guzik TJ, Channon KM. Measurement of vascular reactive oxygen species production by chemiluminescence. Methods Mol Med 2005; 108:73-89.
41. Zhou JY, Prognon P. Raw material enzymatic activity determination: a specific case for validation and comparison of analytical methods: the example of superoxide dismutase (SOD). J Pharm Biomed Anal 2006; 40:1143-1148.
42. Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 1989; 179:8-18.
43. Flohe L, Otting F. Superoxide dismutase assays. Methods Enzymol 1984; 105:93-104.
44. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44:248-252.
45. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42:1075-1081.
46. Durante P, Chávez M, Pérez M, Romero F, Rivera F. Effect of uric acid on hypertension progression in spontaneously hypertensive rats. Life Sci 2010; 86:957-964.
47. Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T. Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system. Circ J 2011; 75:1791-1800.
48. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152:1042-1048.
49. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10:453-471.
50. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1998; 95:4754-4759.
51. DeLano FA, Parks DA, Ruedi JM, Babior BM, Schmid-Schonbein GW. Microvascular display of xanthine oxidase and NADPH oxidase in the spontaneously hypertensive rat. Microcirculation 2006; 13:551-566.
52. Ülker S, McMaster D, McKeown PP, Bayraktutan U. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 2003; 59:488-500.
53. Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, et al. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. Free Radic Biol Med 2005; 38:616-630.
54. Brandes RP, Weissmann N, Schröder K. NADPH oxidases in cardiovascular disease. Free Radic Biol Med 2010; 49:687-706.
55. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH, Janowitz D, et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 2010; 56:490-497.
56. Montenegro MF, Amaral JH, Pinheiro LC, Sakamoto EK, Ferreira GC, Reis RI, et al. Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension. Free Radic Biol Med 2011; 51:144-152.
57. Martinez-Hervas S, Real JT, Ivorra C, Priego A, Chaves FJ, Pallardo FV, et al. Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis 2010; 20:734-739.
58. Li X, Stark GR. NF[kappa]B-dependent signaling pathways. Exp Hematol 2002; 30:285-296.
59. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28:1234-1242.
60. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucl Acids 2008; 27:608-619.
61. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005; 70:343-354.
62. Lodi F, Cogolludo A, Duarte J, Moreno L, Coviello A, Peral De Bruno M, et al. Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. Eur J Pharmacol 2006; 544:97-103.
63. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase in vessels and airways of humans and baboons. Free Radic Biol Med 1996; 20:957-965.
64. Adachi T, Ohta H, Hirano K, Hayashi K, Marklund SL. Nonenzymic glycation of human extracellular superoxide dismutase. Biochem J 1991; 279 (Pt 1):263-267.
65. Romero M, Jiménez R, Hurtado B, Moreno JM, Rodríguez- Gómez I, López-Sepúlveda R, et al. Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur J Pharmacol 2010; 627:242-250.
66. Qu X, Donnelly R. Is insulin resistance in the spontaneously hypertensive rat related to changes in protein kinase c in skeletal muscle? Am J Hypertens 1997; 10:1053-1057.
67. Hulman S, Falkner B, Chen YQ. Insulin resistance in the spontaneously hypertensive rat. Metabolism 1991; 40:359-361.
68. Negre-Salvayre A, Salvayre R, Augãn, Pamplona R, Portero-Otã -n M. Hyperglycemia and. Antioxidants Redox Signal 2009; 11:3071-3109.
69. Wautier J-L, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; 95:233-238.
70. Baumann M, Stehouwer C, Scheijen J, Heemann U, Struijker Boudier H, Schalkwijk C. Ne-(Carboxymethyl)lysine during the early development of hypertension. Ann N Y Acad Sci 2008; 1126:201-204.
71. Wang X, Chang T, Jiang B, Desai K, Wu L. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal[ast]. Am J Hypertens 2007; 20:629-636.
72. Punithavathi VR, Prince PSM, Kumar R, Selvakumari J. Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats. Eur J Pharmacol 2011; 650:465-471.
73. Gebicka L, Didik J. Catalytic scavenging of peroxynitrite by catalase. J Inorganic Biochem 2009; 103:1375-1379.
74. Ghosh S, Janocha AJ, Aronica MA, Swaidani S, Comhair SAA, Xu W, et al. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J Immunol 2006; 176:5587-5597.
75. Tyther R, Ahmeda A, Johns E, Sheehan D. Proteomic identification of tyrosine nitration targets in kidney of spontaneously hypertensive rats. Proteomics 2007; 7:4555-4564.
76. Harrison DG, Chen W, Dikalov S, Li L. Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications. Adv Pharmacol 2010; 60:107-132.
77. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71:247-258.
78. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Molec Cell Endocrinol 2009; 302:148-158.
79. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Molec Cell Endocrinol 2009; 302:128-139.
80. Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem 1993; 268:7562-7570.
81. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinasedependent pathway. J Biol Chem 1997; 272:25968-25975.
82. Gonzalo-Gobernado R, Reimers D, Herranz AS, Rodriguez-Serrano M, C. M, Asensio MJ, et al. Actividad neurotrófica del factor de crecimiento de hígado en un modelo experimental de enfermedad de Parkinson. Congreso de la SENC Tarragona España; 2009.
83. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009; 137: 78-86.
84. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, et al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target 2010; 18:842-848.